(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Vera Therapeutics's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast VERA's revenue for 2026 to be $1,773,694,864, with the lowest VERA revenue forecast at $896,179,634, and the highest VERA revenue forecast at $3,861,585,869. On average, 14 Wall Street analysts forecast VERA's revenue for 2027 to be $17,081,892,928, with the lowest VERA revenue forecast at $9,463,357,152, and the highest VERA revenue forecast at $26,248,349,140.
In 2028, VERA is forecast to generate $47,689,353,203 in revenue, with the lowest revenue forecast at $33,830,132,616 and the highest revenue forecast at $70,405,878,295.